Regeneron Pharmaceuticals Inc. Continues to Impress Investors with Strong Performance
Published on September 5, 2025
Regeneron Pharmaceuticals Inc. (REGN) has been making waves in the stock market recently, with Evercore ISI maintaining a buy rating and a price target of 750. The company's share price has been reflecting positive sentiment around its earnings, and brokerages have set a price target of 829.65. Additionally, Orion Investment Co has boosted its stake in Regeneron, further solidifying investor confidence in the company's future prospects. Overall, Regeneron Pharmaceuticals Inc. is proving to be a strong contender in the pharmaceutical industry, attracting the attention of both analysts and investors alike.
Investor opinions & comments
To leave a comment, you need to Login or Register.
There are no comments yet. Be the first to leave one!